Payment overview · 2025
General Payments
$411.86
21 reported records · 11 companies
Healthcare provider profile · identity verified
Wilbert Roy Warren, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · PHILADELPHIA, PA · NPI 1548228489
Verified facts
What the public records show
CMS Open Payments records show Wilbert Roy Warren, M.D. received $411.86 in general payments during 2025 across 21 reported records.
ABBVIE INC. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $96.34 | 23.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $95.84 | 23.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.47 | 12.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $35.16 | 8.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.79 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.88 | 5.3% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.48 | 5.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.70 | 4.8% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.02 | 3.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.59 | 3.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.59 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $411.86 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.16 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $35.16 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.18 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 115 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 103 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
115 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
103 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 668 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 647 | 186 |
| Losartan Potassium | Losartan Potassium | 497 | 149 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 348 | 106 |
| Gabapentin | Gabapentin | 328 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 286 | 92 |
| Furosemide | Furosemide | 285 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 74 |
| Metformin Hcl | Metformin Hcl | 245 | 77 |
| Lisinopril | Lisinopril | 239 | 72 |
| Omeprazole | Omeprazole | 214 | 63 |
| Famotidine | Famotidine | 207 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 204 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 189 | 66 |
| Pravastatin Sodium | Pravastatin Sodium | 189 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 39 |
| Nifedipine Er | Nifedipine | 177 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 173 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 47 |
| Carvedilol | Carvedilol | 146 | 42 |
| Glipizide Er | Glipizide | 128 | 36 |
| Valsartan | Valsartan | 126 | 33 |
| Alendronate Sodium | Alendronate Sodium | 122 | 33 |
| Allopurinol | Allopurinol | 117 | 33 |
| Eliquis | Apixaban | 115 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 114 | 28 |
| Potassium Chloride | Potassium Chloride | 105 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 26 |
| Januvia | Sitagliptin Phosphate | 102 | 28 |
| Doxepin Hcl | Doxepin Hcl | 95 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 23 |
| Meloxicam | Meloxicam | 88 | 45 |
| Mirtazapine | Mirtazapine | 88 | 31 |
| Metformin Hcl Er | Metformin Hcl | 85 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 84 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 75 | 22 |
| Meclizine Hcl | Meclizine Hcl | 75 | 26 |
| Montelukast Sodium | Montelukast Sodium | 75 | 26 |
| Atenolol | Atenolol | 74 | 22 |
| Ozempic | Semaglutide | 72 | 16 |
| Simvastatin | Simvastatin | 72 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 21 |
| Jardiance | Empagliflozin | 67 | 19 |
| Buspirone Hcl | Buspirone Hcl | 64 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 62 | 20 |
| Chlorthalidone | Chlorthalidone | 61 | 20 |
| Ezetimibe | Ezetimibe | 60 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | suppressed |
| Bumetanide | Bumetanide | 53 | 19 |
| Farxiga | Dapagliflozin Propanediol | 53 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | 16 |
| Spironolactone | Spironolactone | 52 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 39 |
| Xarelto | Rivaroxaban | 52 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Tramadol Hcl | Tramadol Hcl | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 13 |
| Lovastatin | Lovastatin | 45 | 14 |
| Methotrexate | Methotrexate Sodium | 45 | 12 |
| Tiadylt Er | Diltiazem Hcl | 43 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 20 |
| Azelastine Hcl | Azelastine Hcl | 42 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 16 |
| Latanoprost | Latanoprost | 40 | suppressed |
| Felodipine Er | Felodipine | 39 | 12 |
| Methylprednisolone | Methylprednisolone | 39 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Telmisartan | Telmisartan | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 37 | 13 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 21 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 31 | 11 |
| Topiramate | Topiramate | 31 | 13 |
| Naproxen | Naproxen | 30 | 13 |
| Ammonium Lactate | Ammonium Lactate | 28 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Colchicine | Colchicine | 25 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Ciclopirox | Ciclopirox | 22 | suppressed |
| Desloratadine | Desloratadine | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 15 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Calcium Acetate | Calcium Acetate | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $411.86 · 21 records | ABBVIE INC. | ACCRUFER, AREXVY, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, Kerendia, Leqembi, QULIPTA, RAYALDEE, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error